Advertisement

Gallstone Disease: Scientific Understanding and Future Treatment

  • Frank LammertEmail author
Chapter

Abstract

Gallstones are a widespread disease caused by interaction of exogenous and genetic risk factors. The most frequent stones are cholesterol gallbladder stones, which are a consequence of increased hepatic secretion into bile. Multiple genetic factors confer gallstone risk, with the largest effect contributed by a common variant of the hepatic cholesterol transporter ABCG8. A distinct subgroup of patients develops gallstones due to low phosphatidylcholine concentrations in bile, which is caused by ABCB4 transporter defects. Later in the twenty first century, general lifestyle interventions and precise molecular prevention might overcome the current invasive therapy of gallstone disease with cholecystectomy.

Keywords

Laparoscopic Cholecystectomy Cystic Fibrosis Transmembrane Conductance Regulator Bile Duct Stone Gallstone Disease Gallstone Formation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Paumgartner G, Sauter GH. Extracorporeal shock wave lithotripsy of gallstones: 20th anniversary of the first treatment. Eur J Gastroenterol Hepatol. 2005;17:525–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Lammert F, Gurusamy K, Ko CW, Miquel JF, Mendez-Sanchez N, Portincasa P, Van Erpecum KJ, Van Laarhoven CJ, Wang DQ. Gallstones. Nat Rev Dis Primers. 2016;2:16024.Google Scholar
  3. 3.
    Ostrow JD. Unconjugated bilirubin and cholesterol gallstone formation. Hepatology. 1990;12:219S–26S.PubMedGoogle Scholar
  4. 4.
    Sauerbruch T, Stellaard F, Soehendra N, Paumgartner G. Cholesterol content of bile-duct stones. Dtsch Med Wochenschr. 1983;108:1099–102.CrossRefPubMedGoogle Scholar
  5. 5.
    Hirschfield GM, Chapman RW, Karlsen TH, Lammert F, Lazaridis KN, Mason AL. The genetics of complex cholestatic disorders. Gastroenterology. 2013;144:1357–74.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Wang DQ, Cohen DE, Carey MC. Biliary lipids and cholesterol gallstone disease. J Lipid Res. 2009;50:S406–11.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Vitek L, Carey MC. New pathophysiological concepts underlying pathogenesis of pigment gallstones. Clin Res Hepatol Gastroenterol. 2012;36:122–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology. 2005;41:1138–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Lammert F, Sauerbruch T. Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat Clin Pract Gastroenterol Hepatol. 2005;2:423–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Grundy SM. Cholesterol gallstones: a fellow traveler with metabolic syndrome? Am J Clin Nutr. 2004;80:1–2.PubMedGoogle Scholar
  11. 11.
    Biddinger SB, Haas JT, Yu BB, Bezy O, Jing E, Zhang W, Unterman TG, Carey MC, Kahn CR. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med. 2008;14:778–82.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Völzke H, Baumeister SE, Alte D, Hoffmann W, Schwahn C, Simon P, John U, Lerch MM. Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence. Digestion. 2005;71:97–105.CrossRefPubMedGoogle Scholar
  13. 13.
    Aune D, Leitzmann M, Vatten LJ. Physical activity and the risk of gallbladder disease: a systematic review and meta-analysis of cohort studies. J Phys Act Health. 2016;13:788–95. [epub ahead of print]CrossRefPubMedGoogle Scholar
  14. 14.
    Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Glycemic load, glycemic index, and carbohydrate intake in relation to risk of cholecystectomy in women. Gastroenterology. 2005;129:105–12.CrossRefPubMedGoogle Scholar
  15. 15.
    Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Long-chain saturated fatty acids consumption and risk of gallstone disease among men. Ann Surg. 2008;247:95–103.CrossRefPubMedGoogle Scholar
  16. 16.
    Aune D, Norat T, Vatten LJ. Body mass index, abdominal fatness and the risk of gallbladder disease. Eur J Epidemiol. 2015;30:1009–19.CrossRefPubMedGoogle Scholar
  17. 17.
    Aune D, Vatten J. Diabetes mellitus and the risk of gallbladder disease: a systematic review and meta-analysis of prospective studies. J Diabetes Complicat. 2016;30:368–73.CrossRefPubMedGoogle Scholar
  18. 18.
    Buch S, Schafmayer C, Völzke H, Becker C, Franke A, von Eller-Eberstein H, Kluck C, Bässmann I, Brosch M, Lammert F, Miquel JF, Nervi F, Wittig M, Rosskopf D, Timm B, Höll C, Seeger M, ElSharawy A, Lu T, Egberts J, Fändrich F, Fölsch UR, Krawczak M, Schreiber S, Nürnberg P, Tepel J, Hampe J. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet. 2007;39:995–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population. Hepatology. 2011;53:640–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Krawczyk M, Wang DQ, Portincasa P, Lammert F. Dissecting the genetic heterogeneity of gallbladder stone formation. Semin Liver Dis. 2011;31:157–72.CrossRefPubMedGoogle Scholar
  21. 21.
    Von Kampen O, Buch S, Nothnagel M, Azocar L, Molina H, Brosch M, Erhart W, Von Schönfels W, Egberts J, Seeger M, Arlt A, Balschun T, Franke A, Lerch MM, Mayerle J, Kratzer W, Boehm BO, Huse K, Schniewind B, Tiemann K, Jiang ZY, Han TQ, Mittal B, Srivastava A, Fenger M, Jørgensen T, Schirin-Sokhan R, Tönjes A, Wittenburg H, Stumvoll M, Kalthoff H, Lammert F, Tepel J, Puschel K, Becker T, Schreiber S, Platzer M, Völzke H, Krawczak M, Miquel JF, Schafmayer C, Hampe J. Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at the ABCG5/8 lithogenic locus. Hepatology. 2013;57:2407–17.CrossRefPubMedGoogle Scholar
  22. 22.
    Krawczyk M, Lütjohann D, Schirin-Sokhan R, Villarroel L, Nervi F, Pimentel F, Lammert F, Miquel JF. Phytosterol and cholesterol precursor levels indicate increased cholesterol excretion and biosynthesis in gallstone disease. Hepatology. 2012;55:1507–17.CrossRefPubMedGoogle Scholar
  23. 23.
    Buch S, Schafmayer C, Völzke H, Seeger M, Miquel JF, Sookoian SC, Egberts JH, Arlt A, Pirola CJ, Lerch MM, John U, Franke A, von Kampen O, Brosch M, Nothnagel M, Kratzer W, Boehm BO, Bröring DC, Schreiber S, Krawczak M, Hampe J. Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology. 2010;139:1942–51.CrossRefPubMedGoogle Scholar
  24. 24.
    Joshi AD Andersson C, Buch S, Stender S, Noordam R, Weng LC, Weeke PE, Auer PL, Boehm B, Chen C, Choi H, Curhan G, Denny JC, De Vivo I, Eicher JD, Ellinghaus D, Folsom AR, Fuchs C, Gala M, Haessler J, Hofman A, Hu F, Hunter DJ, Janssen HL, Kang JH, Kooperberg C, Kraft P, Kratzer W, Lieb W, Lutsey PL, Darwish Murad S, Nordestgaard BG, Pasquale LR, Reiner AP, Ridker PM, Rimm E, Rose LM, Shaffer CM, Schafmayer C, Tamimi RM, Uitterlinden AG, Völker U, Völzke H, Wakabayashi Y, Wiggs JL, Zhu J, Roden DM, Stricker BH, Tang W, Teumer A, Hampe J, Tybjærg-Hansen A, Chasman DI, Chan AT, Johnson AD. Four susceptibility loci for gallstone disease identified in a meta-analysis of genome-wide association studies. Gastroenterology. 2016; 151(2):351–363.Google Scholar
  25. 25.
    Bustos BI, Pérez-Palma E, Buch S, Azócar L, Moraga C, Toilat M, Hampe J, Nürnberg P, Gutiérrez RA, De Ferrari GV, Miquel JF. Genome-wide association study for gallstone disease in Latin Chilean population. Abstract 910F, presented at the 65th annual meeting of the American Society of Human Genetics. 7 Oct 2015, Baltimore.Google Scholar
  26. 26.
    Poupon R, Rosmorduc O, Boëlle PY, Chrétien Y, Corpechot C, Chazouillères O, Housset C, Barbu V. Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: a study of 156 consecutive patients. Hepatology. 2013;58:1105–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Gudbjartsson DF, Helgason H, Gudjonsson SA, Zink F, Oddson A, Gylfason A, Besenbacher S, Magnusson G, Halldorsson BV, Hjartarson E, Sigurdsson GT, Stacey SN, Frigge ML, Holm H, Saemundsdottir J, Helgadottir HT, Johannsdottir H, Sigfusson G, Thorgeirsson G, Sverrisson JT, Gretarsdottir S, Walters GB, Rafnar T, Thjodleifsson B, Bjornsson ES, Olafsson S, Thorarinsdottir H, Steingrimsdottir T, Gudmundsdottir TS, Theodors A, Jonasson JG, Sigurdsson A, Bjornsdottir G, Jonsson JJ, Thorarensen O, Ludvigsson P, Gudbjartsson H, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Arnar DO, Magnusson OT, Kong A, Masson G, Thorsteinsdottir U, Helgason A, Sulem P, Stefansson K. Large-scale whole-genome sequencing of the Icelandic population. Nat Genet. 2015;47:435–44.Google Scholar
  28. 28.
    Lammert F, Acalovschi M, Ercolani G, van Erpecum KJ, Gurusamy KS, van Laarhoven CJ, Portincasa P; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146–81.Google Scholar
  29. 29.
    Shabanzadeh DM, Sørensen LT, Jørgensen T. A prediction rule for risk stratification of incidentally discovered gallstones: results from a large cohort study. Gastroenterology. 2016;150:156–67.CrossRefPubMedGoogle Scholar
  30. 30.
    Besselink MG, Venneman NG, Go PM, Broeders IA, Siersema PD, Gooszen HG, et al. Is complicated gallstone disease preceded by biliary colic? J Gastrointest Surg. 2009;13:312–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Gutt CN, Encke J, Köninger J, Harnoss JC, Weigand K, Kipfmüller K, et al. Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304). Ann Surg. 2013;258:385–93.CrossRefPubMedGoogle Scholar
  32. 32.
    Giljaca V, Gurusamy KS, Takwoingi Y, Higgie D, Poropat G, Štimac D, Davidson BR. Endoscopic ultrasound versus magnetic resonance cholangiopancreatography for common bile duct stones. Cochrane Database Syst Rev. 2015;2:CD011549.Google Scholar
  33. 33.
    Reinders JS, Goud A, Timmer R, Kruyt PM, Witteman BJ, Smakman N, Breumelhof R, Donkervoort SC, Jansen JM, Heisterkamp J, Grubben M, van Ramshorst B, Boerma D. Early laparoscopic cholecystectomy improves outcomes after endoscopic sphincterotomy for choledochocystolithiasis. Gastroenterology. 2010;138:2315–20.CrossRefPubMedGoogle Scholar
  34. 34.
    Da Costa DW, Bouwense SA, Schepers NJ, Besselink MG, van Santvoort HC, van Brunschot S, Bakker OJ6, Bollen TL, Dejong CH, van Goor H, Boermeester MA, Bruno MJ, van Eijck CH, Timmer R, Weusten B, Consten EC, Brink MA, Spanier BW, Bilgen EJ, Nieuwenhuijs VB, Hofker HS, Rosman C, Voorburg AM, Bosscha K, van Duijvendijk P, Gerritsen JJ, Heisterkamp J, de Hingh IH, Witteman BJ, Kruyt PM, Scheepers JJ, Molenaar IQ, Schaapherder AF, Manusama ER, van der Waaij LA, van Unen J, Dijkgraaf MG, van Ramshorst B, Gooszen HG, Boerma D. Dutch Pancreatitis Study Group. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. Lancet. 2015;386:1261–8.Google Scholar
  35. 35.
    Nealon WH, Bawduniak J, Walser EM. Appropriate timing of cholecystectomy in patients who present with moderate to severe gallstone-associated acute pancreatitis with peripancreatic fluid collections. Ann Surg. 2004;239:741–9.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Lamberts MP, Den Oudsten BL, Gerritsen JJ, Roukema JA, Westert GP, Drenth JP, van Laarhoven CJ. Prospective multicentre cohort study of patient-reported outcomes after cholecystectomy for uncomplicated symptomatic cholecystolithiasis. Br J Surg. 2015;102:1402–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Ko CW, Napolitano PG, Lee SP, Schulte SD, Ciol MA, Beresford SA. Physical activity, maternal metabolic measures, and the incidence of gallbladder sludge or stones during pregnancy: a randomized trial. Am J Perinatol. 2014;31:39–48.CrossRefPubMedGoogle Scholar
  38. 38.
    Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis. 2007;2:29.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Paumgartner U, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36:525–31.CrossRefPubMedGoogle Scholar
  40. 40.
    Stokes CS, Gluud LL, Casper M, Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2014;12:1090–100.CrossRefPubMedGoogle Scholar
  41. 41.
    Delaunay JL, Durand-Schneider AM, Dossier C, Falguières T, Gautherot J, Anne DS, Aït-Slimane T, Housset C, Jacquemin E, Maurice M. A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3. Hepatology. 2015;63:1620–31.Google Scholar
  42. 42.
    Gordo-Gilart R, Andueza S, Hierro L, Jara P, Alvarez L. Functional rescue of trafficking-impaired ABCB4 mutants by chemical chaperones. PLoS One. 2016;11:e0150098. epub ahed of printCrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Kan HP, Guo WB, Tan YF, Zhou J, Liu CD, Huang YQ. Statin use and risk of gallstone disease: a meta-analysis. Hepatol Res. 2014; epub.Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Medicine IISaarland University Medical Center, Saarland UniversityHomburgGermany

Personalised recommendations